Latest news

Global healthtech company Raremark® appoints Nicki Grundy as its Chief Financial Officer

Raremark has strengthened its senior leadership team by hiring the highly experienced Nicki Grundy as its CFO to help drive further growth and improve patient lives.

News.

September 2020

Raremark® implements a new, dynamic executive team to drive patient-centric drug development in rare diseases

Following accelerated levels of growth over the last 6 months, Raremark®, the leading rare disease patient network and real-world insights provider has reasserted its commitment to patient-centric drug development by implementing a new, dynamic executive team to drive the commercial vision and future growth of the company.

News.

August 2020

Raremark® launches the Xperiome™ patient-powered knowledge platform to deliver new therapies faster and smarter

Raremark®, the leading online patient community in rare disease, has today launched its patient-powered knowledge platform Xperiome™ to help the pharmaceutical industry deliver innovative new therapies faster and smarter.

News.

February 2020

Rare Disease Patient Platform Raremark Partners With TriNetX

Raremark, a patient-data platform focused on rare disease, has partnered with the TriNetX network to bring more clinical trials to its community.

News.

October 2018

Patient-data platform Raremark raises £3m to enable precision medicine in rare disease

London, UK – October 22, 2018. Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund.

News.

October 2017

Raremark white paper outlines lessons from a decade of direct-to-patient recruitment

London, UK – October 10, 2017. Medical research can move from good to great if families affected by a rare disease are treated as partners in the clinical trial process, argues a Raremark white paper published today.

Get in touch

Interested in hearing more? Feel free to reach out to us, and we’ll make sure to get back to you as soon as possible.